C4 Therapeutics, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 21.38M33.20M45.78M31.10M20.76M35.58M
Gross Profit 21.38M33.20M45.78M31.10M20.76M35.58M
Operating items
Research & Development 48.06M78.44M94.67M117.84M117.71M110.64M
Selling, General & Administrative 8.77M15.20M33.25M42.79M42.08M42.12M
Restructuring Costs 2.44M
Operating Expenses 56.83M93.64M127.92M160.63M159.79M155.20M
Operating Income -35.45M-60.45M-82.13M-129.53M-139.03M-119.61M
EBIT -35.45M-60.45M-82.13M-129.53M-139.03M-119.61M
Non-operating items
Non Operating Investment Income 0.01M-0.79M-3.36M4.01M0.18M
Interest & Investment Income 2.16M0.39M0.39M3.58M9.81M14.43M
Other Non Operating Income -0.62M
Non Operating Income 2.16M-6.51M-1.76M1.36M7.82M14.43M
Net income details
EBT -33.30M-66.96M-83.89M-128.18M-131.21M-105.19M
Tax Provisions 0.80M-0.63M1.28M0.13M
Profit After Tax -34.10M-66.33M-83.90M-128.20M-132.50M-105.32M
Income from Continuing Operations -34.10M-66.33M-83.89M-128.18M-132.49M-105.32M
Consolidated Net Income -34.10M-66.33M-83.89M-128.18M-132.49M-105.32M
Income towards Parent Company -34.10M-66.33M-83.89M-128.18M-132.49M-105.32M
Preferred Dividend Payments 8.47M
Net Income towards Common Stockholders -42.57M-66.33M-83.89M-128.18M-132.49M-105.32M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 40.77M43.03M48.63M48.96M49.28M70.59M
Shares Outstanding (Diluted Average) 46.04M48.86M49.64M69.37M
EBITDA -34.10M-66.32M-84.68M-131.54M-128.48M-105.14M
Shares Outstanding 1.43M43.06M48.69M48.97M60.47M70.63M
Tax Rate 0.00M